An international study led by CIC bioGUNE identifies key mechanisms of an enzyme involved in a rare metabolic disease
Peer-Reviewed Publication
Updates every hour. Last Updated: 20-Oct-2025 23:11 ET (21-Oct-2025 03:11 GMT/UTC)
An international research team led by CIC bioGUNE has advanced understanding of classical homocystinuria, a rare genetic disorder that impairs the breakdown of homocysteine, causing systemic health issues. Published in The FEBS Journal, the study focuses on the R336C mutation in the CBS enzyme. Contrary to previous beliefs that this mutation denatures the enzyme, researchers found that the enzyme's structure remains mostly intact but exhibits abnormal flexibility. This impairs communication between its cofactor (vitamin B6 derivative) and catalytic site, reducing enzymatic function.
Key findings include:
The R336C mutation causes subtle structural shifts affecting the PLP cofactor’s function.
It disrupts enzyme activity not by structural collapse but by altering its internal dynamics.
The Bateman module, crucial for enzyme regulation, becomes overly mobile, hindering substrate access.
These insights explain poor patient response to vitamin B6 therapy and suggest new treatment strategies, such as drugs to restore cofactor interaction or modulate enzyme flexibility. The study emphasizes the value of international collaboration in rare disease research and the development of personalized medicine.
A team of researchers from Utrecht University, Durham University, and other institutions observed something remarkable at a chimpanzee sanctuary in Zambia. Several chimpanzees from one particular group were seen dangling blades of grass from their ear holes or their behinds, for no apparent reason. The behaviour was not seen in other chimpanzee groups at the same sanctuary, despite similar living conditions. “This shows that, like humans, other animals also copy seemingly pointless behaviours from one another,” says Utrecht University researcher Edwin van Leeuwen. “And that, in turn, may offer insights into the evolutionary roots of human culture.”
POSTECH Achieves First-Ever Ribosomal Synthesis of Cyclic Peptides : Opening New Avenues for Next-Generation Drug Design
Dr. Xuyu Qian, newly appointed Assistant Professor at the University of Pennsylvania and Children's Hospital of Philadelphia, has published groundbreaking research in Nature (2025) mapping human brain development at unprecedented single-cell resolution. His innovative use of spatial transcriptomics to analyze over 18 million cells reveals how the human cerebral cortex forms during fetal development. Combined with his widely-adopted brain organoid protocols (cited over 2,000 times), which helped establish the link between Zika virus and brain malformations, Dr. Qian's human-centric approach promises new therapeutic strategies for neurodevelopmental disorders including autism spectrum disorder and malformations of cortical development.
Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers a roadmap for designing safer, more targeted therapies.
The WEHI-led discovery, published in Science, has uncovered a critical new role for MCL-1, revealing it not only prevents cell death but also provides cells with the energy they need to function.
The findings reshape our understanding of how cells survive and thrive, with implications for both cancer treatment and developmental biology.